Clinical Trials Logo

Filter by:
NCT ID: NCT05150457 Recruiting - Clinical trials for Refractory Solid Tumors

Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors

Start date: February 8, 2022
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety and tolerability of BNA035 in order to determine the maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D) and to evaluate the preliminary efficacy for each combination regimen.

NCT ID: NCT05150236 Active, not recruiting - Prostate Cancer Clinical Trials

EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC

ANZUP2001
Start date: April 29, 2022
Phase: Phase 2
Study type: Interventional

This phase II study will investigate the activity and safety of radionuclide 177Lu-PSMA therapy versus 177Lu-PSMA in combination with Ipilimumab and Nivolumab in patients with metastatic castrate resistant prostate cancer (mCRPC).

NCT ID: NCT05149898 Completed - Clinical trials for 22Q Deletion Syndrome

Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome

INSPIRE
Start date: March 3, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety and tolerability of ZYN002 administered as a transdermal gel formulation, for up to 38 weeks, in patients ages 4 to < 18 years, in the treatment of 22q.11.2 Deletion Syndrome (22qDS).

NCT ID: NCT05149755 Recruiting - Clinical trials for Moderate Aortic Valve Stenosis

Evolutâ„¢ EXPAND TAVR II Pivotal Trial

Start date: April 27, 2022
Phase: N/A
Study type: Interventional

Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.

NCT ID: NCT05148871 Active, not recruiting - COVID-19 Clinical Trials

Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine

Start date: March 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

A study to assess the effect of varying the time interval between doses on the immunogenicity of an adjuvanted recombinant spike protein Covid-19 vaccine (Spikogen/Covax-19)

NCT ID: NCT05147805 Recruiting - Clinical trials for Pulmonary Arterial Hypertension

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Start date: August 24, 2022
Phase: Phase 2
Study type: Interventional

The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.

NCT ID: NCT05146986 Recruiting - Rib; Fracture Clinical Trials

RibFix Blu Thoracic Fixation System Versus Non-surgical Treatment in Non-flail Chest Rib Fractures

Start date: January 2, 2022
Phase:
Study type: Observational

This is a prospective, multi-center, observational, cohort study involving skilled cardiothoracic surgeons who are experienced in implanting the treatment of non-flail chest rib fractures and the use of RibFix Blu Thoracic Fixation System.

NCT ID: NCT05146973 Active, not recruiting - Prostate Cancer Clinical Trials

External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)

Start date: August 30, 2022
Phase: Phase 2
Study type: Interventional

This is a phase II trial to evaluate the therapeutic efficacy of a radiolabelled PSMA-targeting antibody, 177Lu-TLX591, given in combination with external beam radiation therapy (EBRT) in patients with biochemically recurrent, oligometastatic, PSMA-expressing prostate cancer. TLX591 is being developed as a PSMA-targeting antibody to be radiolabelled with a therapeutic radioisotope for the treatment of PSMA-expressing tumours.

NCT ID: NCT05146206 Completed - Allergic Rhinitis Clinical Trials

Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray

Start date: November 8, 2021
Phase:
Study type: Observational

The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).

NCT ID: NCT05145010 Enrolling by invitation - Achondroplasia Clinical Trials

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Start date: December 6, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, open-label, extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR 1-3-selective tyrosine kinase inhibitor, in subjects with ACH who previously completed a QED-sponsored interventional study, and potentially in additional subjects who are naïve to infigratinib treatment. Quality of Life assessments for this subject population will also be evaluated. Treatment-naïve subjects must have at least a 6-month period of growth assessment in the PROPEL study (Protocol QBGJ398 001) and will be enrolled in this OLE study only after a dose to be explored further is identified in Phase 2 Study QBGJ398-201.